Longboard Pharmaceuticals Overview
- Year Founded
-
2020

- Status
-
Public
- Employees
-
33

- Share Price
-
$59.98
- (As of Friday Closing)
Longboard Pharmaceuticals General Information
Description
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.
Contact Information
Website
www.longboardpharma.comCorporate Office
- 4275 Executive Square
- Suite 950
- La Jolla, CA 92037
- United States
Corporate Office
- 4275 Executive Square
- Suite 950
- La Jolla, CA 92037
- United States
Longboard Pharmaceuticals Timeline
Longboard Pharmaceuticals Stock Performance
As of 29-Nov-2024, Longboard Pharmaceuticals’s stock price is $59.98. Its current market cap is $2.34B with 39M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$59.98 | $59.96 | $3.65 - $60.03 | $2.34B | 39M | 1.72M | -$2.25 |
Longboard Pharmaceuticals Financials Summary
As of 30-Sep-2024, Longboard Pharmaceuticals has a trailing 12-month revenue of null.
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | 995,510 | 88,345 | (20,368) | (27,945) |
Revenue | 0 | 0 | 0 | 0 |
EBITDA | (87,599) | (56,822) | (44,777) | (27,860) |
Net Income | (76,344) | (54,422) | (43,945) | (27,797) |
Total Assets | 297,005 | 50,697 | 70,616 | 108,952 |
Total Debt | 3,734 | 475 | 740 | 524 |
Longboard Pharmaceuticals Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Longboard Pharmaceuticals Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
Longboard Pharmaceuticals Comparisons
Industry
Financing
Details
Longboard Pharmaceuticals Competitors (3)
One of Longboard Pharmaceuticals’s 3 competitors is Neurogene, a Formerly VC-backed company based in New York, NY.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Neurogene | Formerly VC-backed | New York, NY | ||||
Neurona Therapeutics | Venture Capital-Backed | South San Francisco, CA | ||||
Cerebral Therapeutics | Venture Capital-Backed | Aurora, CO |
Longboard Pharmaceuticals Signals
Longboard Pharmaceuticals Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Longboard Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated February, 16, 2024
21.42 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,120
Rank
Percentile

Commercial Services
Industry
of 428
Rank
Percentile

Business Support Services
Subindustry
of 171
Rank
Percentile

Longboard Pharmaceuticals FAQs
-
When was Longboard Pharmaceuticals founded?
Longboard Pharmaceuticals was founded in 2020.
-
Where is Longboard Pharmaceuticals headquartered?
Longboard Pharmaceuticals is headquartered in La Jolla, CA.
-
What is the size of Longboard Pharmaceuticals?
Longboard Pharmaceuticals has 33 total employees.
-
What industry is Longboard Pharmaceuticals in?
Longboard Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Longboard Pharmaceuticals a private or public company?
Longboard Pharmaceuticals is a Public company.
-
What is the current stock price of Longboard Pharmaceuticals?
As of 29-Nov-2024 the stock price of Longboard Pharmaceuticals is $59.98.
-
What is the current market cap of Longboard Pharmaceuticals?
The current market capitalization of Longboard Pharmaceuticals is $2.34B.
-
Who are Longboard Pharmaceuticals’s competitors?
Neurogene, Neurona Therapeutics, and Cerebral Therapeutics are competitors of Longboard Pharmaceuticals.
-
What is Longboard Pharmaceuticals’s annual earnings per share (EPS)?
Longboard Pharmaceuticals’s EPS for 12 months was -$2.25.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »